Treatments
Complementary and Alternative Treatments
- Physical treatments
- Repurposed Drugs – General
- No medication – Plan B
- Repurposed drugs and chemotherapy
- Repurposed drugs and radiation therapy
- FLCCC’s ranking of repurposed drugs
- Brain metastases and the blood-brain barrier
- Bombs, fire extinguishers, and timing
Plaquenil (hydroxychloroquin) and cancer
Indhold:
- Plaquenil (hydroxychloroquin) and cancer (scroll down)
- Antiparasitic drugs – compariso (scroll to)
Summary of Plaquenil
Strategic purpose:
- To function as a metabolic “blockade” that prevents cancer cells from repairing themselves. This is crucial in a metabolic cocktail, as it prevents cancer cells from surviving the stress imposed on them by other repurposed drugs (e.g., Metformin or Ivermectin).
Metabolic function:
- Plaquenil works by changing the acidity in the cell’s lysosomes (the digestive system). This stops the “recycling station” (autophagy) and blocks the uptake of nutrients from the surroundings, slowly “suffocating” the cell in its own waste.
Role in a protocol:
- The substance acts as a “force multiplier.” It is primarily used to enhance the effect of other agents in cancer treatment. When other substances pressure the cancer cell, Plaquenil removes the cell’s ability to withstand that pressure.
What is Plaquenil
Plaquenil (hydroxychloroquine/HCQ) is known as an antimalarial drug, but in integrative cancer treatment, it has a completely different and far more vital function. Here, it is regarded as a metabolic blockade.
Where chemotherapy and radiation attempt to kill the cancer cell directly by damaging its DNA, Plaquenil works by sabotaging the cell’s internal logistics and “digestion.” It is a cornerstone in several self-treatment protocols (such as those described in parts of the FLCCC) because it attacks two fundamental survival mechanisms that aggressive cancer cells are deeply dependent on to resist treatment: autophagy and macropinocytosis (the cell’s intake of nutrients).
Intake
Should be taken with a meal or a glass of milk/fatty drink. This increases absorption and reduces the risk of gastrointestinal discomfort.
The Recycling Station (Autophagy)
This is the primary reason the drug is included in protocols, and it is often where the battle must be won to avoid resistance. Cancer cells have an extremely high metabolism.
They produce large amounts of waste and damaged proteins, especially when pressured by chemotherapy or radiation. To survive this—and to survive in areas of the tumor with low oxygen supply—they use a process called autophagy (“self-eating”).
They break down their own waste in the cell’s lysosomes (the cell’s digestive system, which requires an acidic environment) and recycle it as new energy. It is their ultimate survival kit.
Plaquenil’s effect
Plaquenil is alkaline and penetrates these lysosomes, where it neutralizes the acid. Without an acidic environment, the enzymes that break down the waste do not function.
Consequence:
- The cancer cell’s “trash can” is not emptied. Waste accumulates, and the cell cannot regain energy for repair. It slowly “suffocates” from within in toxic waste and loses the ability to repair the damage inflicted by other treatments. [1, 3]
This is particularly effective against cancer stem cells (CSC), which specifically use autophagy to enter dormancy and survive standard treatment, only to later create recurrence or metastases.
Food Intake (Macropinocytosis)
Many aggressive cancers (especially those with KRAS mutations, such as pancreatic and colorectal cancer) depend on “stealing” proteins from their surroundings to grow. They do this via a process called macropinocytosis (“cell-drinking”), where they swallow large chunks of surrounding tissue.
Plaquenil blocks this process effectively. Once the cell has “swallowed” the proteins, they must be digested in the lysosomes to become usable amino acids. Because Plaquenil has destroyed the acidity in the lysosomes, the cell cannot digest the food. It effectively starves to death, even though it is full of nutrients. [6]
Synergy with other repurposed drugs
For users of protocols (such as Joe Tippens, Jane McLelland, or similar), it is crucial to understand how Plaquenil interacts with other agents. It should not stand alone—it is a team player that makes other agents more dangerous to the cancer.
Synergy with mTOR inhibitors (e.g., metformin)
Metformin and berberine inhibit the signaling pathway mTOR (the growth signal). When mTOR is inhibited, the cancer cell automatically attempts to activate autophagy to survive the energy shortage. If one takes metformin without blocking autophagy, one provides the cancer cell with an escape route. By taking Plaquenil alongside metformin, the escape route is closed. Metformin pressures the cell’s energy, and Plaquenil prevents it from adapting to the pressure. This is a classic “hammer and anvil” principle.
Synergy with ivermectin/ fenbendazole
While antiparasitic agents like ivermectin and fenbendazole attack the cell’s “skeleton” (microtubules) and energy production, Plaquenil ensures the cell cannot clean up after the damage.
Furthermore, these agents hit all cancer stem cells via different mechanisms, increasing the chance of total eradication of tumor growth. [5]
Synergy with statiner
Statins inhibit the production of cholesterol (necessary for cell membranes), which stresses the cell. Plaquenil prevents the cell from managing this stress via autophagy.
See also Repurposed drugs
See also The parasite’s path to cancer
Immune effect and micro-environment
Plaquenil does more than stress the cell internally—it also changes the battlefield around the cell.
Dampening of inflammation
Plaquenil inhibits Toll-like receptors (the immune system’s alarm system, TLR). Many tumors create chronic inflammation around themselves to promote growth and keep the body’s killer cells away. By dampening TLR signals, one removes some of this “fuel” from the fire and makes the environment less hospitable for the tumor.
Normalization of blood vessels
Tumors form chaotic, leaky blood vessels to obtain blood quickly. Research suggests that Plaquenil (and chloroquine) can normalize these vessels. For patients receiving chemotherapy, this means the medicine can better reach the tumor’s core. It also means better oxygenation, making radiation therapy significantly more effective, as radiation requires oxygen to work.
Geminis svar
Plaquenil (hydroxychloroquine) and cancer
Content:
- Plaquenil (scroll to)
- Antiparasitic agents compared (scroll to)
Summary of Plaquenil
Strategic purpose: To function as a metabolic “blockade” that prevents cancer cells from repairing themselves. This is crucial in a metabolic cocktail, as it prevents cancer cells from surviving the stress imposed on them by other repurposed drugs (e.g., Metformin or Ivermectin).
Metabolic function: Plaquenil works by changing the acidity in the cell’s lysosomes (the digestive system). This stops the “recycling station” (autophagy) and blocks the uptake of nutrients from the surroundings, slowly “suffocating” the cell in its own waste.
Role in a protocol: The substance acts as a “force multiplier.” It is primarily used to enhance the effect of other agents in cancer treatment. When other substances pressure the cancer cell, Plaquenil removes the cell’s ability to withstand that pressure.
What is Plaquenil
Plaquenil (hydroxychloroquine/HCQ) is known as an antimalarial drug, but in integrative cancer treatment, it has a completely different and far more vital function. Here, it is regarded as a metabolic blockade.
Where chemotherapy and radiation attempt to kill the cancer cell directly by damaging its DNA, Plaquenil works by sabotaging the cell’s internal logistics and “digestion.” It is a cornerstone in several self-treatment protocols (such as those described in parts of the FLCCC) because it attacks two fundamental survival mechanisms that aggressive cancer cells are deeply dependent on to resist treatment: autophagy and macropinocytosis (the cell’s intake of nutrients).
Intake
Should be taken with a meal or a glass of milk/fatty drink. This increases absorption and reduces the risk of gastrointestinal discomfort.
The Recycling Station (Autophagy)
This is the primary reason the drug is included in protocols, and it is often where the battle must be won to avoid resistance. Cancer cells have an extremely high metabolism. They produce large amounts of waste and damaged proteins, especially when pressured by chemotherapy or radiation. To survive this—and to survive in areas of the tumor with low oxygen supply—they use a process called autophagy (“self-eating”). They break down their own waste in the cell’s lysosomes (the cell’s digestive system, which requires an acidic environment) and recycle it as new energy. It is their ultimate survival kit.
Plaquenil’s effect: Plaquenil is alkaline and penetrates these lysosomes, where it neutralizes the acid. Without an acidic environment, the enzymes that break down the waste do not function.
Consequence: The cancer cell’s “trash can” is not emptied. Waste accumulates, and the cell cannot regain energy for repair. It slowly “suffocates” from within in toxic waste and loses the ability to repair the damage inflicted by other treatments. [1, 3] This is particularly effective against cancer stem cells (CSC), which specifically use autophagy to enter dormancy and survive standard treatment, only to later create recurrence or metastases.
Food Intake (Macropinocytosis)
Many aggressive cancers (especially those with KRAS mutations, such as pancreatic and colorectal cancer) depend on “stealing” proteins from their surroundings to grow. They do this via a process called macropinocytosis (“cell-drinking”), where they swallow large chunks of surrounding tissue.
Plaquenil blocks this process effectively. Once the cell has “swallowed” the proteins, they must be digested in the lysosomes to become usable amino acids. Because Plaquenil has destroyed the acidity in the lysosomes, the cell cannot digest the food. It effectively starves to death, even though it is full of nutrients. [6]
Synergy with other repurposed drugs
For users of protocols (such as Joe Tippens, Jane McLelland, or similar), it is crucial to understand how Plaquenil interacts with other agents. It should not stand alone—it is a team player that makes other agents more dangerous to the cancer.
Synergy with mTOR inhibitors (e.g., metformin): Metformin and berberine inhibit the signaling pathway mTOR (the growth signal). When mTOR is inhibited, the cancer cell automatically attempts to activate autophagy to survive the energy shortage. If one takes metformin without blocking autophagy, one provides the cancer cell with an escape route. By taking Plaquenil alongside metformin, the escape route is closed. Metformin pressures the cell’s energy, and Plaquenil prevents it from adapting to the pressure. This is a classic “hammer and anvil” principle.
Synergy with ivermectin/fenbendazole: While antiparasitic agents like ivermectin and fenbendazole attack the cell’s “skeleton” (microtubules) and energy production, Plaquenil ensures the cell cannot clean up after the damage. Furthermore, these agents hit all cancer stem cells via different mechanisms, increasing the chance of total eradication of tumor growth. [5]
Synergy with statins: Statins inhibit the production of cholesterol (necessary for cell membranes), which stresses the cell. Plaquenil prevents the cell from managing this stress via autophagy.
See also Repurposed drugs See also The parasite’s path to cancer
Immune effect and microenvironment
Plaquenil does more than stress the cell internally—it also changes the battlefield around the cell.
Dampening of inflammation: Plaquenil inhibits Toll-like receptors (the immune system’s alarm system, TLR). Many tumors create chronic inflammation around themselves to promote growth and keep the body’s killer cells away. By dampening TLR signals, one removes some of this “fuel” from the fire and makes the environment less hospitable for the tumor.
Normalization of blood vessels: Tumors form chaotic, leaky blood vessels to obtain blood quickly. Research suggests that Plaquenil (and chloroquine) can normalize these vessels. For patients receiving chemotherapy, this means the medicine can better reach the tumor’s core. It also means better oxygenation, making radiation therapy significantly more effective, as radiation requires oxygen to work.
Specifically on Pancreatic Cancer
In pancreatic cancer, Plaquenil plays a special role in research. This type of cancer is often driven by a mutation in the KRAS gene, making the tumor extremely dependent on both autophagy and macropinocytosis (ingestion of nutrients) to survive. Because cancer cells here live in very oxygen-poor and “scarred” tissue, chemotherapy often struggles to work alone. Studies indicate that Plaquenil may be the key to breaking this resistance because it hits precisely the two mechanisms that keep KRAS-mutated cells alive. [6]
Why antiparasitic medicine works against cancer
The connection between parasites and cancer is not accidental. Using antiparasitic agents like Plaquenil, Ivermectin, or Mebendazole against cancer is based on fundamental biological similarities between a parasite and a malignant tumor. They share a number of survival strategies that make them vulnerable to the same type of medicine.
1. The metabolic common denominator
Both parasites and cancer cells differ from normal cells by their extreme metabolic needs. They must grow and divide explosively in an environment that is often hostile.
- Glucose dependency: Both types of cells often exhibit what is called the Warburg effect – an inefficient but rapid burning of sugar (aerobic glycolysis). Many antiparasitic agents, including Plaquenil, interfere with this energy production.
2. Signaling pathways and stem cell properties
Cancer stem cells (CSC) are the cells in a tumor that drive growth and are responsible for relapse. These cells share traits with parasites by being “immortal” and able to go into dormancy to avoid treatment. They both reuse powerful “growth programs” (such as Wnt and Notch). [10]
- Both parasites and cancer stem cells reuse the powerful ‘growth programs’ (such as Wnt and Notch), which the body otherwise only uses when a fetus is being formed.
- While traditional chemotherapy often targets dividing cells, antiparasitic agents often hit these signaling pathways, which can target the very “root” of the cancer. [10]
3. Immune evasion
- A parasite can only survive if it can trick the host’s immune system into not attacking. Cancer cells use the same tactic; they emit signals that slow down the immune system (immunosuppression).
Reactivation of Chemotherapy
Resistance is a major challenge in cancer treatment. Cancer cells that survive the first round of chemotherapy often do so by upregulating autophagy to repair DNA damage.
By combining chemotherapy with Plaquenil, this escape route is cut off. The chemo damages the cell, and Plaquenil prevents the repair.
This concept, called chemosensitizing, is documented in several studies, including in head and neck cancer, where cisplatin resistance was overcome. [2]
Safety and Side Effects
Plaquenil is a potent drug. For those assembling a protocol, safety is paramount to avoid harming the body during the fight.
Eyes – the greatest risk
With long-term use, the substance can accumulate in the eye’s pigment cells and damage the retina (retinopathy). This is rare but serious, as it can cause permanent vision damage.
- Requirements: If you use Plaquenil in a fixed protocol over several months, you must see an ophthalmologist at least once a year (preferably every 6 months at high doses).
Warning: Interaction with chemotherapy
There is a known, specific contraindication between Plaquenil and the chemotherapy drug Etoposide. Research shows the two should not be combined as it may inhibit the chemo’s effect or lead to unpredictable toxicity.
Furthermore, Plaquenil in rare cases has its own suppressive effect on bone marrow.
If you are in chemo treatment that already pushes your platelets and white blood cells to the limit, the addition of Plaquenil could cause the bone marrow to collapse (agranulocytosis).
Always discuss your blood counts with your oncologist before mixing Plaquenil with chemo.
The Heart (QT prolongation)
Plaquenil can affect heart rhythm. This is particularly critical if you combine it with other substances that do the same. Be especially aware of combinations with:
- Certain types of antibiotics (macrolides like azithromycin).
- Certain anti-nausea medications (Zofran/ondansetron).
- Certain antidepressants (SSRIs). Always check your combinations in the interaction database.
Gastrointestinal
Nausea and stomach pain are common. It often helps to take the tablet with a meal containing fat, as this reduces irritation of the stomach lining.
Interaktioner (search for preparations) (Interaktionsdatabasen, Danish Medicines Agency) [8]
Research
Research into Plaquenil as a cancer drug is moving from preclinical trials to clinical human studies. Unfortunately, there is little financial interest from pharmaceutical companies, so grants for such studies are scarce.
Combination effects
A study published in 2025 showed that combining hydroxychloroquine with the agonist 2-BFI can achieve a significantly enhanced cell-killing effect in colorectal cancer cells.
The combination increased oxidative stress and led to a collapse in their energy metabolism. This underscores that Plaquenil should rarely stand alone. [1, 9]
Pancreatic cancer
As mentioned, there is significant attention on the drug for pancreatic cancer. This form is notoriously difficult to treat and extremely dependent on autophagy. Several studies investigate if adding Plaquenil to standard treatment (like gemcitabine) can extend survival by suffocating the tumors’ energy supply. [4]
Clinical observations
Data indicates that patients with autoimmune diseases in long-term Plaquenil treatment may have an altered cancer risk profile, supporting the hypothesis of a protective or therapeutic effect. [3]
Conclusion
For the cancer patient seeking ways outside the standard system offerings—or where standard offerings are exhausted—Plaquenil represents a strategic necessity rather than just an “alternative.”
It is not a miracle cure on its own. However, its ability to block the cancer cell’s most potent survival mechanism (autophagy) makes it a “force multiplier” that can be the difference between treatment success and failure.
By depriving cancer cells of the ability to repair damage and adapt to stress, one tips the balance in favor of the patient.
Interactions (search for preparations) (Interaktionsdatabasen, Danish Medicines Agency)
See also Ivermectin’s immunotoxic effect
See also The parasite’s path to cancer
See also Repurposed Drugs
See also Cancer treatment based on the Mitochondrial Stem Cell Connection
See also No medicine – Plan B
To be continued…
Links
[1] Hydroxychloroquine: Key therapeutic advances and clinical applications (ScienceDirect, 2023)
- Content: An in-depth scientific review from 2023. The article describes in detail how HCQ raises the pH in the lysosomes and thus blocks autophagy. It concludes that the substance is promising both as monotherapy and especially in combination with other treatments.
[2] Malaria drug could combat chemotherapy-resistant head and neck cancers (ecancer, 2022)
- Content: An article about a study from the University of Pittsburgh showing that hydroxychloroquine can overcome resistance to the chemo drug cisplatin. The article explains how cancer cells use autophagy to evade chemo, and how HCQ blocks this escape route.
[3] Repurposing Drugs in Oncology (ReDO)—Chloroquine and hydroxychloroquine as anti-cancer agents (Ecancer, Medical Science, 2017)
- Content: The main work from the ReDO project. A complete and extremely thorough review collecting all evidence for the use of chloroquine and hydroxychloroquine against a wide range of cancers. Indispensable for those wanting to dive deep into the data.
[4] Autophagy inhibitors for cancer therapy: Small molecules targeting autophagy (ScienceDirect, 2023)
- Content: A technical article explaining the biology behind resistance. It emphasizes that without an autophagy inhibitor (like Plaquenil), many treatments will lose their effect over time because the cancer learns to repair itself.
[5] Ivermectin, a potential anticancer drug derived from an antiparasitic agent (Science Direct, 2021)
- Content: Relevant for the cocktail approach. Describes ivermectin’s mechanisms, making it possible to see the synergy with Plaquenil’s cleanup blockade.
[6] Evidence-based complementary treatment of pancreatic cancer (Dove Medical Press, 2018)
- Content: A review of supplementary treatments for pancreatic cancer, including hydroxychloroquine. The article is central because it specifically addresses the use of HCQ to target this cancer form’s special metabolic dependency (autophagy/macropinocytosis), which makes it difficult to treat conventionally.
[7] The imidazoline I2 receptor agonist 2-BFI enhances cytotoxic activity of hydroxychloroquine (PubMed, 2025)
- Content: A study showing the future of combination treatments. It documents how HCQ’s effect can be enhanced by further stressing the cell (oxidative stress) and causing the energy metabolism to collapse in cancer cells.
[8] Hydroxychloroquine (Drugs.com, 2024)
- Content: Detailed information on side effects, dosages, and contraindications. Important for safety checks.
[9] Phase I trial of hydroxychloroquine to enhance palbociclib (Nature, 2025)
- Content: A clinical study investigating the effect of combining hydroxychloroquine with the cancer drug palbociclib. Research indicates that the combination can enhance the effect against breast cancer cells, potentially reducing the need for high doses and thereby reducing side effects.
[10] Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol (Journal of Orthomolecular Medicine, 2024)
- Content: The article introduces a “hybrid protocol” combining repurposed drugs (such as doxycycline) and supplements. The purpose is specifically to hit cancer stem cells by cutting off their energy supply in the mitochondria, supporting the metabolic approach where Plaquenil is also included.
Page created: July 1, 2024, Last revised December 12, 2025
To be continued…
❤
What you read on Jeg har Kræft is not a recommendation. Seek competent guidance.
Antiparasitic drugs – compariso
Short summary of differences and similarities
Although several antiparasitic agents are being investigated for their effect against cancer, they work in widely different ways:
Mebendazole:
- Destroys the cancer cell’s internal “skeleton” (microtubules) to stop cell division. Among the drugs mentioned here, it is the one most extensively studied in clinical trials.
Fenbendazole:
- Also destroys the cell’s “skeleton” but is additionally believed to create metabolic stress. It has a strong anecdotal history.
Niclosamide:
- Interrupts the cell’s energy supply while simultaneously blocking its growth signals.
Ivermectin:
- Creates internal stress in the cell and prevents it from pumping out chemotherapy, which can counteract resistance.
Hydroxychloroquine:
- Blocks the cell’s “recycling system” (autophagy), causing it to succumb to its own waste.
The point is that these different mechanisms allow for strategic combinations where cancer can be attacked from multiple angles simultaneously to achieve a stronger effect.
Antiparasitic agents compared
One of the most promising areas within complementary and experimental cancer treatment is repurposed drugs. A particularly interesting group consists of antiparasitic agents. Many of these substances have proven to possess potent anticancer properties, but it is crucial to understand that they do not all work the same way. Their attacks on cancer cells are widely different.
Below is a comparison of the most discussed substances and their unique mechanisms of action to provide a clear overview of their individual strengths and potential.
Mebendazole (Vermox)
- Main mechanism: Destruction of microtubules (the cell’s scaffolding)
- Mebendazole’s primary and most well-documented effect is a disruption of the cancer cells’ internal skeleton. The substance, which belongs to the benzimidazole family, works by binding to the protein tubulin and preventing it from assembling into microtubules. This effectively stops cell division (mitosis) and leads to cell death. Mebendazole is also the benzimidazole that has been the subject of the most formal clinical investigations, especially in connection with aggressive brain tumors (glioblastoma), where it has been tested as a supplement to standard chemotherapy.
- Characteristics: A direct, physical attack on the cell’s structure. It is the benzimidazole most extensively studied in human clinical trials.
See also links at the bottom of this article
Fenbendazole
Main mechanism: Destruction of microtubules (the cell’s scaffolding).
- Fenbendazole shares the same core mechanism as mebendazole, namely destroying the cancer cells’ microtubules and thereby stopping cell division. Its popularity, however, is driven more by preclinical studies (laboratory and animal trials) as well as strong patient reports and compelling anecdotal evidence.
Secondary mechanisms:
- In addition to the microtubule effect, research indicates that fenbendazole has a unique ability to stress the metabolism of cancer cells by blocking their sugar uptake. Certain studies also indicate that it can reactivate the tumor-suppressor gene p53.
Characteristics:
- Characterized by having a strong anecdotal history and a research focus on its ability to create metabolic stress.
See also links at the bottom of this article
Niclosamide
Niclosamide takes a completely different approach, which is primarily metabolic and signal-oriented.
Main mechanism: Metabolic collapse (energy blockade)
- Niclosamide acts as an “uncoupler” in the cancer cell’s power plants, the mitochondria. It simply short-circuits the process that produces energy (ATP), leading to an immediate and fatal loss of energy in the cell. Simultaneously, massive oxidative stress is created (via ROS production), further damaging the cell.
Secondary, but crucial mechanism: Signaling sabotage
- Beyond the energy blockade, niclosamide’s great strength is its ability to simultaneously inhibit a wide range of central signaling pathways that cancer cells depend on (Wnt, STAT3, mTOR, NF-κB). This hits not only growth but also the otherwise resilient cancer stem cells.
Characteristics:
- A dual attack that both removes the cell’s fuel and interrupts its internal communication.
See also links at the bottom of this article
Ivermectin
Ivermectin is again different from those mentioned above, working broadly on several systems related to cell stress and transport.
Main mechanism: Induction of oxidative stress and ion imbalance
- Like niclosamide, ivermectin can create high levels of oxidative stress (ROS) that are toxic to the cancer cell. It is also believed to affect ion channels in the cell membrane, disrupting the fragile electrical balance the cell maintains.
Secondary, but crucial mechanism: Inhibition of transport pumps
- One of the main causes of chemoresistance is that cancer cells develop pumps (such as P-glycoprotein) that actively push chemotherapy back out of the cell. Ivermectin has been shown to block these pumps. This means it can make resistant cancer cells sensitive to chemotherapy again, as the poison now remains inside the cell.
Characteristics:
- Creates internal stress and prevents the cancer cell from “pumping” out toxins.
See also links at the bottom of this article
Hydroxychloroquine (Plaquenil)
This drug, which is an antimalarial agent, has a very specific and unique mechanism.
Main mechanism: Blocking autophagy (the cell’s recycling station)
- Autophagy is a survival mechanism where the cell breaks down and recycles its own damaged parts to obtain energy and building blocks under pressure (e.g., during chemotherapy). Hydroxychloroquine blocks this process. The result is that the cancer cell cannot “clean up” after itself, leading to an accumulation of toxic waste inside. This makes the cell significantly more vulnerable and can push it toward cell death, especially when it is already stressed by other treatments.
Characteristics:
- Prevents the cancer cell from “eating itself” to survive pressure.
See also links at the bottom of this article
Artemisinin (and derivatives)
Main mechanism: Iron-activated cell death via free radicals
- Artemisinin, originally a Nobel Prize-winning drug for malaria, has a highly effective and specific mechanism of action. Cancer cells need large amounts of iron to divide rapidly, and they therefore have a much higher concentration of iron than normal, healthy cells. The artemisinin molecule contains a special chemical structure (an endoperoxide bridge) that reacts violently when it comes into contact with iron. This reaction creates an explosion of unstable and highly damaging molecules called free radicals (specifically Reactive Oxygen Species, ROS). This internal “bomb” of oxidative stress destroys the cancer cell’s membranes, proteins, and DNA from within, forcing it into cell death. The process has similarities to a specific type of cell death called ferroptosis (iron-dependent cell death).
Access in Denmark:
- The pure, most potent substance artesunate (a derivative) is a prescription drug in Denmark, while the plant Artemisia annua is typically sold as a dietary supplement.
Characteristics:
- Functions as a “Trojan horse” that exploits the cancer cell’s own iron dependency to create a targeted internal explosion.
See also links at the bottom of this article
Overview
| Drug | Primary Mechanism of Action | Unique Characteristics |
| Mebendazole | Destruction of microtubules | Attacks the cell’s “skeleton.” Most studied in clinical trials. |
| Fenbendazole | Destruction of microtubules | Attacks the cell’s “skeleton.” Strong anecdotal history. |
| Niclosamide | Metabolic collapse (energy blockade) | Removes cell fuel and sabotages signaling pathways. Poor absorption. |
| Ivermectin | Induction of oxidative stress / Inhibition of pumps | Creates internal stress and counteracts chemoresistance. |
| Hydroxychloroquine | Inhibition of autophagy | Prevents the cell’s “recycling system” from working. |
| Artemisinin (and derivatives) | Iron-activated formation of free radicals (ROS) | Exploits high iron content in cancer cells to create oxidative stress. |
Conclusion
The clear conclusion is that there is no single “antiparasitic” effect against cancer. Each substance represents a unique angle of attack that exploits different vulnerabilities in the cancer cell’s complex machinery. This diversity opens the door for intelligent combination treatments, where a tumor can be hit from several sides simultaneously. In the long run, a deeper understanding of these mechanisms can lead to more tailored treatment, where the choice of a repurposed drug is based on the specific biochemical profile of the individual tumor. The potential lies not in a single “miracle cure,” but in the strategic use of an entire arsenal of different, rediscovered “keys,” each of which can unlock a new door in the cancer cell’s defense.
As these are medications, it is naturally essential to discuss their use with your healthcare provider.
See also Metabolic strategy – block signaling pathways by cancer type – chart overviews
If you are in doubt about interaction, it can be checked here:
See also Repurposed Drugs
See also No medicine – Plan B
Se også The parasite’s path to cancer
Links
Ivermectin:
Ivermectin, a potential anticancer drug derived from an antiparasitic agent (Science Direct, 2021)
- Relevance: This article provides a broad overview of the many proposed anti-cancer mechanisms for ivermectin. It mentions, among other things, the effect on Hippo, Akt/mTOR, and WNT signaling pathways, which supports the drug’s versatility.
The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer (EMBO Molecular Medicine, 2014)
- Relevance: A very specific study confirming that ivermectin is an effective blocker of the WNT signaling pathway, which is a fundamental and often overactive signaling pathway in many cancers, including colorectal and breast cancer.
- Relevance: An animal study shows that the drug ivermectin has a strong anti-cancer effect on non-small cell lung cancer (NSCLC). The study concludes that ivermectin works by blocking the central growth signaling pathway (EGFR/PI3K/AKT/mTOR), leading to increased cell death and inhibited tumor growth.
Ivermectin and Cancer: Exploring the Potential Link (Williams Cancer Institute, 2023)
- Relevance: Ivermectin has potential as a cancer treatment by inhibiting tumor growth, inducing apoptosis, strengthening the immune system, and preventing angiogenesis. These mechanisms may supplement existing therapies, but further clinical research is necessary. Overall, Ivermectin opens new possibilities for the development of innovative cancer treatments.
Ivermectin, a potential anticancer drug derived from an antiparasitic drug (Science Direct, 2021)
- Relevance: Ivermectin, an antiparasitic macrolide, has shown promising potential as a cancer treatment by inhibiting tumor cell proliferation and promoting apoptosis through multiple signaling pathways. This opens possibilities for clinical use of ivermectin as an anti-neoplastic agent. Further research is needed to realize this potential in cancer treatment.
Fenbendazole:
Fenbendazole, Ivermectin and Mebendazole for Breast Cancer Success Stories – 37 Case Reports (The Medical Adviser, June 2025)
- Relevance: Several peer-reviewed articles and case studies suggest that Fenbendazole, Ivermectin, and Mebendazole may play an important role in the treatment of stage 4 breast cancer. Research shows that these substances have different anti-cancer mechanisms that can be effective against cancer cells. Specific studies include a protocol for Ivermectin, as well as investigations of Fenbendazole and Mebendazole in relation to breast cancer and metastases.
- Relevance: Fenbendazole can kill both common cancer cells and the difficult cancer stem cells in cervical cancer by disrupting the cells’ growth cycle. It stopped tumor growth in animal models without weight loss, in contrast to chemotherapy, and resulted in full survival in those treated. These results make fenbendazole a promising treatment choice against cervical cancer.
Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study (PubMed, 2024)
- Relevance: Fenbendazole can inhibit the growth and promote the death of ovarian cancer cells by disrupting the cell cycle and causing mitotic catastrophe. It was also shown to reduce tumor growth in mice, suggesting it could become a promising treatment for ovarian cancer. These results open possibilities for new therapies against this serious disease.
Mebendazole:
Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (PubMed, 2021)
- Relevance: Albendazole and mebendazole are broad-spectrum deworming medications that block microtubules and have shown promising anti-cancer effects in vitro and in vivo. They can be used against parasitic infections and potentially as cancer treatment, but long-term use can cause side effects like liver damage. Mebendazole is currently more popular in cancer trials due to albendazole’s toxicity.
- Relevance: Mebendazole and paclitaxel have a synergistic effect on inhibiting proliferation and microtubular structures in oral tongue squamous cell carcinoma (OTSCC) by inhibiting the PI3K/AKT signaling pathway. The combination increases apoptosis markers and may be a promising treatment for OTSCC. Further research is needed to confirm their clinical potential.
In vitro evaluation of lipidic nanocarriers for mebendazole delivery to improve anticancer activity (PubMed, 2024)
- Relevance: Mebendazole nanostructures (MBZ-NLCs) are stable and contain a larger portion of the active substance than standard forms. They are ten times more effective against cancer cells and can prevent the movement of cancer cells in laboratory experiments. The results suggest that mebendazole nanostructures could become a good treatment for lung cancer, but more tests in the body are needed.
Plaquenil:
- Relevance: A new study shows that the substance 2-BFI (an imidazoline I2-receptor agonist) significantly enhances the cell-killing effect of the autophagy inhibitor hydroxychloroquine (HCQ) against colorectal cancer cells. The combination works by creating increased oxidative stress and disrupting cancer cell metabolism and survival mechanisms.
Malaria Drug Could Combat Chemotherapy-Resistant Head and Neck Cancers (UPMC, 2022)
- Relevance: This is an easy-to-understand summary of a study that shows a concrete example of how hydroxychloroquine is used to overcome chemo-resistance. It explains how the substance can “re-sensitize” cancer cells so that chemotherapy works again.
Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents (PubMed, 2017)
- Relevance: Chloroquine (CQ) and hydroxychloroquine (HCQ) have potential as anti-cancer treatment, especially in combination with standard therapies. They affect both cancer cells and the tumor microenvironment through autophagy inhibition and modulation of signaling pathways such as p53 and CXCR4-CXCL12. Further clinical studies are necessary to optimize dosing and treatment regimens.
Niclosamide:
- Relevance: This study identified 35 genes, including CDK1 and TTK, as important targets in ovarian cancer, which often develops resistance to treatment. NSC765690 (MCC22) was found to be a promising niclosamide analog with strong activity against both targets, which may help overcome chemotherapy resistance. The results show a data-driven approach to developing new therapies for ovarian cancer.
Niclosamide Treatment Suppressed Metastatic, Apoptotic, and Proliferative Characteristics of MDA-MB-231 Cancer Stem Cells (PubMed, 2025)
- Relevance: This study showed that niclosamide effectively induces apoptosis and stops the cell cycle in aggressive triple-negative breast cancer-CSCs in a 3D model. The treatment reduced metastasis- and resistance-related genes as well as EMT markers, which may improve treatment effectiveness against cancer. The results suggest that niclosamide can increase CSC sensitivity and prevent tumor recurrence.
Pharmacological advances and therapeutic applications of niclosamide in cancer and other diseases (PubMed, 2025)
- Relevance: Niclosamide is an FDA-approved drug with potential in cancer treatment, especially against resistant ovarian cancer, by modulating cell proliferation and apoptosis. New formulations and nanotechnology improve bioavailability, strengthening its therapeutic possibilities. It shows promising versatility in the treatment of cancer, viral infection, and inflammatory diseases.
- Relevance: NHC, an improved form of niclosamide, shows increased solubility and potential as a treatment for colon cancer. The analysis confirms that NHC is more effective than NES, and metabolomics as well as 16S rRNA investigate its mechanism. This may open new possibilities for niclosamide-based cancer treatment.
Antitumor activity of niclosamide-mediated oxidative stress against acute lymphoblastic leukemia (PubMed, 2024)
- Relevance: Niclosamide was shown to be able to inhibit growth and induce apoptosis in acute lymphoblastic leukemia (ALL) by increasing reactive oxygen species and activating TP53. It has potential as a new treatment to improve response and extend survival in ALL patients. These results indicate that niclosamide could become a promising therapeutic agent against ALL.
In General:
Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol (Journal of Orthomolecular Medicine)
Interactions (search for preparations) (Interaktionsdatabasen, Danish Medicines Agency)
Page created: July 1, 2024, Last revised July 2, 2025
❤
What you read on Jeg har Kræft is not a recommendation. Seek competent guidance.